A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Conditions

• Advanced Malignant Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BMS-986488 — DRUG
  Specified dose on specified days
• Adagrasib — DRUG
  Specified dose on specified days
• Cetuximab — DRUG
  Specified dose on specified days
• Nivolumab — DRUG
  Specified dose on specified days

Study Details

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Key Dates

Start date

Mar 25, 2025

Status verified

Jun 2026

Primary completion

Oct 15, 2027

Completion

Oct 15, 2027

Study Design

Enrollment

437 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1A: BMS-986488 Monotherapy
• Experimental: Part 1B: BMS-986488 + Adagrasib
• Experimental: Part 1C: BMS-986488 + Adagrasib + Cetuximab
• Experimental: Part 1D: BMS-986488 + Nivolumab
• Experimental: Part 2A: BMS-986488 Monotherapy
• Experimental: Part 2B: BMS-986488 + Adagrasib
• Experimental: Part 2C: BMS-986488 + Adagrasib + Cetuximab
• Experimental: Part 2D: BMS-986488 + Nivolumab

Primary Outcome Measure

Number of participants with Adverse Events (AEs) [ Time Frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose) ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Locations (4)

Find similar trials in Hackensack, NJ